The Sentante robot is a haptic endovascular robotic platform using standard cath lab equipment, such as guidewires and catheters. These devices connect to a system equipped with a high-resolution sensory platform capturing the specialist’s hand movements.
A robot at the patient’s bedside replicates these manipulations in real-time, whether nearby or thousands of miles away. Unlike joystick-controlled surgical robots, it delivers authentic force feedback to the surgeon’s fingertips, the company says. This recreates the tactile experience of manual surgery.
The tele-operated system enables life-saving interventions from seated positions at high-resolution screens displaying X-ray imagery. This frees surgeons from radiation exposure and the physical strain of standing for prolonged periods.
Lithuania-based Sentante earned FDA breakthrough device designation in September 2025. The company then reported a first-of-its-kind remote procedure with its platform in November 2025. With acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) earlier this year, CE mark now represents the latest milestone for the robot.
(Learn more about the surgical robotics space in our MassDevice Surgical Robotics Special Report. Download the report for free here.)
Sentante says it wants to find a way to close the gap in endovascular intervention through thrombectomy. Other companies, like Remedy Robotics, are also advancing robotic thrombectomy technologies. Microbot Medical and EndoQuest Robotics also develop endovascular robotic systems.
CE mark enables the company to begin marketing and selling the platform across European markets. It plans to begin an initial rollout alongside clinical training as it expands its commercial footprint. The company also seeks to advance its product pipeline.
Sentante recently unveiled a digital indeflator. The precision-controlled system replaces the traditional manual indeflator used in endovascular procedures like angioplasty and stent deployment.
“This is a defining moment for Sentante,” said Edvardas Satkauskas, CEO and co-founder of Sentante. “Achieving CE mark is not only a validation of our technology, but also of the rigorous work undertaken by our team to meet the highest regulatory standards. We are now positioned to move decisively into commercialization and begin delivering real impact for clinicians and patients.”
